1.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 04-22, 11PAN01, NCT01360853
|
|
2.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MM-398-07-03-01, NCT01494506
|
|
3.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EMR 200592-001, 2012-002957-42, NCT01746979
|
|
4.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: CDR0000573370, UMDNJ-0120070076, 0120070076, NCT00553683
|
|
5.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 120 Sponsor: Other Protocol IDs: 2007-0910, NCT00769483
|
|
6.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: Neogenix 0901, NCT01040000
|
|
7.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 14865, NCT01303159
|
|
8.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BBI608-201, NCT01325441
|
|
9.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 13663, H9H-MC-JBAJ, NCT01373164
|
|
10.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CMEK162X2109, 2011-002578-21, NCT01449058
|
|
11.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: PCRT 11-002, NCT01488552
|
|
12.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: LCCC 2009-608, NCT01489865
|
|
13.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UPCC 19211, NCT01506973
|
|
14.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 120111, 12-C-0111, NCT01583686
|
|
15.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 65 Sponsor: Pharmaceutical / Industry Protocol IDs: M402-103, NCT01621243
|
|
16.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 14453, I2H-MC-JWYD, NCT01632306
|
|
17.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 90 Sponsor: Pharmaceutical / Industry Protocol IDs: 59R5-002, NCT01647828
|
|
18.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000360863, UTHSC-MS-02117, NCT00082862
|
|
19.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: CTCA06-02, NCT00323583
|
|
20.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000580812, UPCC-04206, GENENTECH-UPCC-04206, UPCC-805957, NCT00602602
|
|
21.
|
Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: GRID, NCT00765570
|
|
22.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: KLT-PANC-001, NCT00733850
|
|
23.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: INST 0802, NCI-2011-02731, NCT00871169
|
|
24.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 011438, IND #103,981, 2008-437, NCT00881621
|
|
25.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 0911010739, NCT01053013
|